Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 21, 2013; 19(39): 6515-6522
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6515
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6515
Table 2 Components of the risk scores
| Factor | Risk score | ||
| CU-HCC | GAG-HCC (yr) | REACH-B | |
| Age (yr) | ≤ 50: 0 | 30-34: 0 | |
| >50: 3 | 35-39: 1 | ||
| 40-44: 2 | |||
| 45-49: 3 | |||
| 50-54: 4 | |||
| 55-59: 5 | |||
| 60-65: 6 | |||
| Sex | NA | Male: 16 | Male: 2 |
| Female: 0 | Female: 0 | ||
| Albumin (g/L) | ≤ 35: 20 | NA | NA |
| > 35: 0 | |||
| Bilirubin (mmol/L) | ≤ 18: 0 | NA | NA |
| > 18: 1.5 | |||
| ALT (U/L) | NA | NA | < 15: 0 |
| 15-44: 1 | |||
| ≥ 45: 2 | |||
| HBeAg | NA | NA | Positive: 2 |
| Negative: 0 | |||
| HBV DNA (copies/mL) | < 4 log: 0 | 3 × in log | < 4 log: 0 |
| 4-6 log: 1 | 4-5 log: 3 | ||
| > 6 log: 4 | 5-6 log: 5 | ||
| (lack of maintained virologic suppression: 4) | ≥ 6 log: 4 (lack of maintained virologic suppression: 4) | ||
| Cirrhosis | Presence: 15 | Presence: 33 | NA |
| Absence: 0 | Absence: 0 | ||
- Citation: Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522
- URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6515.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i39.6515